rosiglitazone has been researched along with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bosshardt, DD; Buser, D; Gemperli, AC; Gruber, R; Miron, RJ; Sculean, A | 1 |
1 other study(ies) available for rosiglitazone and 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide
Article | Year |
---|---|
Enamel matrix derivative inhibits adipocyte differentiation of 3T3-L1 cells via activation of TGF-βRI kinase activity.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Benzamides; Cell Differentiation; Connective Tissue Growth Factor; Dental Enamel Proteins; Dioxoles; Gene Expression Regulation; Hot Temperature; Indomethacin; Mice; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta | 2013 |